RxDoctor Payments Data

Reagan Owens, APRN

Nurse Practitioner · Montgomery, ALNPI 1659077709

Payments from drug & device makers

$1,281in general payments, 2019–2025

Across 52 payments — averaging $24.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$390
  • Amgen$179
  • AbbVie$167
  • AstraZeneca$101
  • Novo Nordisk$92
  • Sumitomo Pharma America, Inc.$92
  • plus $261 from 8 others

What the payments were for

  • Food & beverage$1,281100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,281 in reported general payments places this provider in the 75th percentile of 1,505 nurse practitioner providers in Alabama.

See all nurse practitioner providers in Alabama

Medicare billing

Part B allowed, 2024
$26,422
Medicare patients
89
Services billed
440

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide120$170,149
MounjaroTirzepatide69$89,976
LinzessLinaclotide54$76,163
JardianceEmpagliflozin56$74,629
RybelsusSemaglutide25$71,608
FarxigaDapagliflozin Propanediol49$67,609
TrulicityDulaglutide32$63,591
EliquisApixaban35$47,259
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$39,638
GemtesaVibegron25$32,428
JanuviaSitagliptin Phosphate18$30,547
XareltoRivaroxaban19$24,934
VascepaIcosapent Ethyl21$16,752
EntrestoSacubitril/Valsartan11$16,480
Janumet XrSitagliptin Phos/Metformin Hcl15$15,538

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$92$241,757145 claims
Lilly USA, LLCMounjaro, Trulicity$40$153,567101 claims
AstraZenecaFarxiga, Breztri Aerosphere$101$80,31464 claims
AbbVieLinzess$167$76,16354 claims
Boehringer IngelheimJardiance$25$74,62956 claims
MerckJanuvia, Janumet Xr, Janumet$20$52,33245 claims
GSKTrelegy Ellipta, Anoro Ellipta$390$46,50552 claims
Sumitomo Pharma America, Inc.Gemtesa$92$32,42825 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,505 nurse practitioner providers in Alabama.

Other nurse practitioner in Montgomery

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →